Actions
  • shareshare
  • link
  • cite
  • add
add
auto_awesome_motion View all 7 versions
Publication . Article . 2015

Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function Analyses of the EMPHASIS-HF Study Subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)

Romain Eschalier; John J.V. McMurray; Karl Swedberg; D.J. Veldhuisen van; Henry Krum; Stuart J. Pocock; Harry Shi; +4 Authors
Open Access
English
Published: 01 Sep 2015 Journal: Journal of the American College of Cardiology, issue 17, pages 1,585-1,593 (issn: 07351097, Copyright policy )
Publisher: American College of Cardiology Foundation. Published by Elsevier Inc.
Abstract

ObjectivesThe study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2 and serum potassium 5.5, >6.0, and 5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events. Eplerenone was effective in reducing the primary composite endpoint in all subgroups.ConclusionsIn patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m2 and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF. (A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180)

Subjects by Vocabulary

Microsoft Academic Graph classification: Heart failure medicine.disease medicine business.industry business Renal function Cardiology medicine.medical_specialty In patient Eplerenone medicine.drug Internal medicine Survival study Hyperkalemia medicine.symptom

Library of Congress Subject Headings: lcsh:Therapeutics. Pharmacology lcsh:RM1-950 lcsh:Diseases of the circulatory (Cardiovascular) system lcsh:RC666-701

Subjects

chronic kidney disease, diabetes, efficacy, elderly, eplerenone, safety, Pharmacology (medical), Cardiology and Cardiovascular Medicine, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701, CHRONIC KIDNEY-DISEASE, MEDICAL THERAPY, ALDOSTERONE, SPIRONOLACTONE, PROTEINURIA, DYSFUNCTION, ANTAGONISTS, TRIAL, AGE, хроническая болезнь почек, сахарный диабет, эффективность, пожилые пациенты, эплеренон, безопасность

22 references, page 1 of 3

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.

2. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364: 11-21. [OpenAIRE]

3. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. [OpenAIRE]

4. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69.

5. Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009;302:1658-65.

6. Zannad F, McMurray JJV, Drexler H, et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010;12:617-22. [OpenAIRE]

7. Weidmann P, De Myttenaere-Bursztein S, Maxwell MH, De Lima J. Effect on aging on plasma renin and aldosterone in normal man. Kidney Int 1975;8:325-33. [OpenAIRE]

8. Henschkowski J, Stuck AE, Frey BM, et al. Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients. Am J Hypertens 2008;21:644-9.

9. Krug AW, Allenhöfer L, Monticone R, et al. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 2010;55:1476-83.

10. Johnson ES, Weinstein JR, Thorp ML, et al. Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiol Drug Saf 2010;19:266-72.

moresidebar